Biotech Values

[DewDiligence]

FDA advisory panel voted 19-2 to_include_an omicron component in a potential fall-2022 booster. The panel was not asked to vote on whether the booster should be monovalent or bivalent, but there was a clear preference among the panelists for bivalent. The panel was also not asked to vote on whether the omicron component of the booster should be B.1 or B.4/5, but there was a slight preference among the panelists for B.4/5. The panel’s opinions are not binding on the FDA or the CDC.